NASDAQ:KMDA Kamada (KMDA) Stock Price, News & Analysis → Urgent new message from Porter Stansberry (From Porter & Company) (Ad) Free KMDA Stock Alerts $5.83 -0.04 (-0.68%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$5.83▼$5.8350-Day Range$5.58▼$6.4252-Week Range$4.08▼$6.53Volume779 shsAverage Volume24,324 shsMarket Capitalization$335.05 millionP/E Ratio38.87Dividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kamada alerts: Email Address Kamada MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside88.7% Upside$11.00 Price TargetShort InterestHealthy0.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 13 Articles This WeekInsider TradingN/AProj. Earnings Growth78.26%From $0.23 to $0.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.92 out of 5 starsMedical Sector233rd out of 946 stocksPharmaceutical Preparations Industry103rd out of 437 stocks 3.5 Analyst's Opinion Consensus RatingKamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Kamada has a forecasted upside of 88.7% from its current price of $5.83.Amount of Analyst CoverageKamada has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.17% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently increased by 9.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKamada does not currently pay a dividend.Dividend GrowthKamada does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KMDA. Previous Next 3.0 News and Social Media Coverage News SentimentKamada has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Kamada this week, compared to 1 article on an average week.Search Interest7 people have searched for KMDA on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows1 people have added Kamada to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kamada insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.08% of the stock of Kamada is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Kamada are expected to grow by 78.26% in the coming year, from $0.23 to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kamada is 38.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Kamada is 38.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 179.51.Price to Book Value per Share RatioKamada has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Kamada Stock (NASDAQ:KMDA)Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.Read More KMDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KMDA Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comKMDA Apr 2024 10.000 callMarch 16, 2024 | americanbankingnews.comBrokers Set Expectations for Kamada Ltd.'s FY2024 Earnings (NASDAQ:KMDA)March 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 14, 2024 | americanbankingnews.comKamada Ltd. Expected to Earn Q1 2024 Earnings of $0.05 Per Share (NASDAQ:KMDA)March 13, 2024 | finance.yahoo.comKMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…March 11, 2024 | americanbankingnews.comFY2024 Earnings Forecast for Kamada Ltd. Issued By HC Wainwright (NASDAQ:KMDA)March 9, 2024 | americanbankingnews.comKamada (NASDAQ:KMDA) Given "Buy" Rating at HC WainwrightMarch 9, 2024 | americanbankingnews.comKamada Ltd. (NASDAQ:KMDA) Forecasted to Earn Q1 2024 Earnings of $0.07 Per ShareMarch 19, 2024 | Advantage Gold (Ad)RIP U.S. Dollar (04/1792 - 10/2024)Mark Levin: Guard your money NOW Mark Levin has seen it all as America’s #1 political commentator. But he’s warning Americans that he’s never seen things this bad. Government spending threatens to destroy our economy. Reckless policies continue to fuel inflation and threaten the US Dollar. And it’s your retirement savings that could ultimately pay the price. Join this 100% free Wealth Summit to see how to protect yourself now.March 7, 2024 | benzinga.comPreview: Kamada's EarningsMarch 7, 2024 | markets.businessinsider.comStrategic Partnerships and Product Portfolio Expansion Poise Kamada for Robust GrowthMarch 7, 2024 | finance.yahoo.comKamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | msn.comFootball: Kubo, Kamada exit Champions League as Sociedad, Lazio loseMarch 6, 2024 | washingtonpost.comKamada: Q4 Earnings SnapshotMarch 6, 2024 | investorplace.comKMDA Stock Earnings: Kamada Beats EPS, Misses Revenue for Q4 2023March 6, 2024 | globenewswire.comKamada Issues 2024 CEO Letter to ShareholdersMarch 6, 2024 | globenewswire.comKamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and ProfitabilityFebruary 28, 2024 | globenewswire.comKamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024February 22, 2024 | benzinga.comKamada Stock (NASDAQ:KMDA) Dividends: History, Yield and DatesFebruary 8, 2024 | wsj.comKamada Ltd.January 31, 2024 | stocknews.com3 Pharma Gems Driving Profits NowJanuary 12, 2024 | stocknews.comWill These 3 Pharma Stocks Become Gainers in 2024?December 8, 2023 | seekingalpha.comKamada: Kedrion Deal Locks In GrowthDecember 7, 2023 | msn.comKMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…December 7, 2023 | finance.yahoo.comKEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®December 7, 2023 | marketwatch.comKamada Shares Hit 52-Week High After Extending Agreement With KedrionNovember 15, 2023 | finance.yahoo.comKMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…See More Headlines Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/16/2023Today3/19/2024Next Earnings (Estimated)5/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KMDA CUSIPN/A CIK1567529 Webwww.kamada.com Phone(728) 940-6472Fax972-8940-6473Employees380Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+87.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.15 Trailing P/E Ratio39.13 Forward P/E Ratio25.52 P/E GrowthN/ANet Income$8.28 million Net Margins5.81% Pretax Margin5.91% Return on Equity5.66% Return on Assets3.57% Debt Debt-to-Equity RatioN/A Current Ratio3.43 Quick Ratio1.64 Sales & Book Value Annual Sales$142.52 million Price / Sales2.37 Cash Flow$0.45 per share Price / Cash Flow13.09 Book Value$4.25 per share Price / Book1.38Miscellaneous Outstanding Shares57,470,000Free Float36,726,000Market Cap$337.35 million OptionableOptionable Beta1.05 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Amir London (Age 55)Chief Executive Officer Comp: $619kMr. Chaime Orlev (Age 54)Chief Financial Officer Comp: $396kMr. Eran Nir (Age 51)Chief Operating Officer Comp: $371kMr. Boris Gorelik (Age 43)Vice President of Business Development & Strategic Programs Comp: $337kMr. David Tsur (Age 74)Co-Founder & Deputy Chairman of the Board Comp: $252kMr. Nir Livneh B.A. (Age 45)L.L.B., VP, General Counsel & Corporate Secretary Ms. Hanni Neheman (Age 54)Vice President of Marketing & Sales Ms. Liron Reshef (Age 53)Vice President of Human Resources Mr. Jon R. KnightVice President of US Commercial OperationsMs. Shavit BeladevVice President of Kamada PlasmaMore ExecutivesKey CompetitorsPepGenNASDAQ:PEPGAtea PharmaceuticalsNASDAQ:AVIRNature's Sunshine ProductsNASDAQ:NATRErascaNASDAQ:ERASNeoleukin TherapeuticsNASDAQ:NLTXView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 202,558 shares on 3/11/2024Ownership: 2.130%Vanguard Group Inc.Bought 202,558 shares on 2/15/2024Ownership: 2.130%Citadel Advisors LLCBought 26,600 shares on 2/15/2024Ownership: 0.000%Aristides Capital LLCBought 16,635 shares on 2/13/2024Ownership: 0.099%UBS Group AGBought 73,076 shares on 2/9/2024Ownership: 0.131%View All Institutional Transactions KMDA Stock Analysis - Frequently Asked Questions Should I buy or sell Kamada stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KMDA shares. View KMDA analyst ratings or view top-rated stocks. What is Kamada's stock price target for 2024? 1 equities research analysts have issued 1 year price objectives for Kamada's shares. Their KMDA share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price. View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts. How have KMDA shares performed in 2024? Kamada's stock was trading at $6.12 on January 1st, 2024. Since then, KMDA shares have decreased by 4.7% and is now trading at $5.83. View the best growth stocks for 2024 here. Are investors shorting Kamada? Kamada saw a increase in short interest in February. As of February 29th, there was short interest totaling 51,900 shares, an increase of 10.0% from the February 14th total of 47,200 shares. Based on an average trading volume of 69,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.2% of the shares of the stock are short sold. View Kamada's Short Interest. When is Kamada's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our KMDA earnings forecast. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) released its quarterly earnings results on Wednesday, August, 16th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to analysts' expectations of $34.18 million. Kamada had a net margin of 5.81% and a trailing twelve-month return on equity of 5.66%. During the same quarter last year, the firm posted $0.07 earnings per share. What guidance has Kamada issued on next quarter's earnings? Kamada updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $156.0 million-$160.0 million, compared to the consensus revenue estimate of $166.1 million. What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW). Who are Kamada's major shareholders? Kamada's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.13%), Vanguard Group Inc. (2.13%), Altshuler Shaham Ltd (0.23%), UBS Group AG (0.13%), Aristides Capital LLC (0.10%) and Simplex Trading LLC (0.00%). How do I buy shares of Kamada? Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KMDA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe world’s greatest investmentPorter & CompanyBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.